Meeting of the Internal Medicine Sciences’ Council of the Department of Medical Sciences of the Russian Academy of Sciences "Achievements of therapy — 2024" on February 13, 2025, as part of the XIV International Internet Congress for Internists

Internal Medicine Sciences’ Council of the Russian Academy of Sciences, rheumatology, gastroenterology, repositioning, bowel disease, non-alcoholic fatty liver disease

1. Zuriaga MA, Yu Z, Matesanz N, et al. Colchicine prevents ac­ce­lerated atherosclerosis development in TET2-mutant clonal he­matopoiesis. EurHeart J. 2023;4(Suppl 2),ehad655.3264. doi:10.1093/eurheartj/ehad655.3264.

2. Fiolet ATL, Poorthuis MHF, Opstal TSJ, et al. Colchicine for se­con­dary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials. EClinicalMedicine. 2024; 76:102835. doi:10.1016/j.eclinm.2024.102835.

3. Tramujas L, Nogueira A, Felix N, et al. Association of col­chi­cine use with cardiovascular and limb events in peripheral artery disease: Insights from a retrospective cohort study. Athe­ro­scle­ro­sis. 2024;398:118563. doi:10.1016/j.atherosclerosis.2024.118563.

4. Nidorf SM, Fiolet ATL, Mosterd A, et al. LoDoCo2 Trial In­vest­iga­tors. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838-47. doi:10.1056/NEJMoa2021372.

5. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019; 381(26):2497-505. doi:10.1056/NEJMoa1912388.

6. Cipolletta E, Nakafero G, McCormick N, et al. Cardiovascular events in patients with gout initiating urate-­lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data. Lancet Rheumatol. 2025;7(3):e197-e207. doi:10.1016/S2665-9913(24)00248-0.

7. Heijman MWJ, Fiolet ATL, Mosterd A, et al. Association of Low-­Dose Colchicine with Incidence of Knee and Hip Replacements: Exploratory Analyses from a Randomized, Controlled, Double-­Blind Trial. Ann Intern Med. 2023;176(6):737-42. doi:10.7326/M23-0289.

8. Bliddal H, Bays H, Czernichow S, et al. Once-­Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024;391(17):1573-83. doi:10.1056/NEJMoa2403664.

9. Karacabeyli D, Lacaille D, Lu N, et al. Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-­mediated inflammatory diseases and type 2 diabetes: A population-­based study. PLoS One. 2024;19(8):e0308533. doi:10.1371/journal.pone.0308533.

10. Wang A, Shi W, Zhang N, et al. Newer Glucose-­Lowering Drugs and Risk of Gout: A Network Meta-­Analysis of Randomized Out­comes Trials. Clin Ther. 2024;46(11):851-4. doi:10.1016/j.clinthera.2024.04.013.

11. Yokose C, McCormick N, Abhishek A, et al. The clinical benefits of sodium-­glucose cotransporter type 2 inhibitors in people with gout. Nat Rev Rheumatol. 2024;20(4):216-31. doi:10.1038/s41584-024-01092-x.

12. Wei J, Choi HK, Dalbeth N, et al. Gout Flares and Mortality After Sodium-­Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes. JAMA Netw Open. 2023;6(8):e2330885. doi:10.1001/jamanetworkopen.2023.30885.

13. Zhang S, Wang Q, Tan DEL, et al. Gut-liver axis: Potential mechanisms of action of food-derived extracellular vesicles. J Extracell Vesicles. 2024;13(6):e12466. doi:10.1002/jev2.12466.

14. Fan YH, Zhang S, Wang Y, et al. Inter-organ metabolic interaction networks in non-alcoholic fatty liver disease. Front Endocri­nol (Lausanne). 2025;15:1494560. doi:10.3389/fendo.2024.1494560.

15. Rigor J, Martins ME, Passos B, et al. Noninvasive tools for the assessment of fibrosis in metabolic dysfunction-­associated steatotic liver disease. Minerva Med. 2024;115(6):660-70. doi:10.23736/S0026-4806.24.09290-5.

16. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-­associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. doi:10.1016/j.jhep.2024.04.031.

17. Rugge M, Genta RM, Malfertheiner P, et al. RE.GA.IN.: the Real-world Gastritis Initiative-­updating the updates. Gut. 2024;73(3):407-41. doi:10.1136/gutjnl-2023-331164.

18. Chen YC, Malfertheiner P, Yu HT, et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Can­cer Between 1980 and 2022 [published correction appears in Gastro­ente­ro­logy. 2025;168(4):850. doi:10.1053/j.gastro.2025.01.008]. Gastroenterology. 2024;166(4):605-19. doi:10.1053/j.gastro.2023.12.022.

19. Alexandrescu L, Suceveanu AP, Stanigut AM, et al. Intestinal Insights: The Gut Microbiome's Role in Atherosclerotic Disease: A Narrative Review. Microorganisms. 2024;12(11):2341. doi:10.3390/microorganisms12112341.

20. Malan-­Müller S, Martín-­Hernández D, Caso JR, et al. Meta­ge­nomic symphony of the intestinal ecosystem: How the composi­tion affects the mind. Brain Behav Immun. 2025;123:510-23. doi:10.1016/j.bbi.2024.09.033.

21. Aggeletopoulou I, Triantos C. Microbiome Shifts and Their Impact on Gut Physiology in Irritable Bowel Syndrome. Int J Mol Sci. 2024;25(22):12395. doi:10.3390/ijms252212395.

22. Cantón R, De Lucas Ramos P, García-­Botella A, et al. Human intestinal microbiome: Role in health and disease. Rev Esp Quimioter. 2024;37(6):438-53. doi:10.37201/req/056.2024.

23. Bicbavova GR, Drapkina OM, Livzan MA, et al. Cardiovascular risk factors in patients with ulcerative colitis. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(8):658-63. (In Russ.) doi:10.26442/00403660.2023.08.202338.

24. Zhao Y, Yang H, Wu P, et al. Akkermansia muciniphila: A promising probiotic against inflammation and metabolic disorders. Virulence. 2024;15(1):2375555. doi:10.1080/21505594.2024.2375555.

25. Bicbavova GR, Livzan MA, Drapkina OM, et al. Sarcopenia and Dinapenia in Patients with Ulcerative Colitis (Cross-­Sectional Observational Study). Annals of the Russian academy of medical sciences. 2024;79(2):112-22. (In Russ.) doi:10.15690/vramn17389.

26. Livzan MA, Bikbavova GR, Lisyutenko NS, et al. Cardiovascular Risk in Patients with Inflammatory Bowel Diseases-­The Role of Endothelial Dysfunction. Diagnostics (Basel). 2024;14(16):1722. doi:10.3390/diagnostics14161722.

27. Massironi S, Franchina M, Elvevi A, et al. Beyond the gluten-free diet: Innovations in celiac disease therapeutics. World J Gastroenterol. 2024;30(38):4194-210. doi:10.3748/wjg.v30.i38.4194.